In the post-pandemic COVID-19 period, human activities have returned to normal and
COVID-19 cases are usually mild. However, patients with multiple myeloma (MM) present an …

Patients with multiple myeloma frequently present with substantial immune impairment and
an increased risk for infections and infection-related mortality. The risk for infection with …

Patients with multiple myeloma (MM) seem to be at increased risk for more severe COVID-
19 infection and associated complications due to their immunocompromised state, the older …

The rapid development of safe and effective vaccines is imperative to attenuate the impact of
the COVID-19 pandemic. 1 Patients with multiple myeloma (MM) are at increased risk of …

Recent data suggest a suboptimal antibody response to COVID-19 vaccination in patients
with hematological malignancies. Neutralizing antibodies (NAbs) against SARS-CoV-2 were …

Multiple myeloma (MM) patients are at higher risk for severe COVID-19. Their mRNA
vaccination response against SARS-CoV-2 is unknown. Thus, we analyzed responses to …

Patients with multiple myeloma have a compromised immune system, due to both the
disease and antimyeloma therapies, and may therefore be particularly susceptible to COVID …

The primary cause of morbidity and mortality in patients with multiple myeloma (MM) is an
infection. Therefore, there is great concern about susceptibility to the outcome of COVID-19 …

Background The COVID-19 pandemic, caused by SARS-CoV-2 virus, has resulted in over
100,000 deaths in the USA. Our institution has treated over 2000 COVID-19 patients during …

Background Safety and immunogenicity of BNT162b2 mRNA vaccine are unknown in
hematological patients; both were evaluated prospectively in 42 patients with multiple …